Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 13/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22896493 | 0.87 | CAPN1 (0.44) | CAPN1CTSS | |
| SCHEMBL22896420 | 0.87 | HDAC6 (0.41) | CAPN1CTSSKDM4EGAA | |
| SCHEMBL22896292 | 0.87 | CAPN1 (0.50) | CAPN1CTSS | |
| SCHEMBL22896305 | 0.84 | CAPN1 (0.39) | CAPN1F2POLBSMN1; SMN2KDM4E | |
| SCHEMBL22895925 | 0.84 | CAPN1 (0.43) | CAPN1CTSS | |
| SCHEMBL22896434 | 0.84 | CAPN1 (0.42) | CAPN1CTSS | |
| SCHEMBL22896708 | 0.83 | USP30 (0.44) | USP30CAPN1RAB9AF2ESR1 | |
| SCHEMBL22895857 | 0.83 | USP30 (0.40) | USP30CAPN1RAB9AF2CTSS | |
| SCHEMBL22896441 | 0.83 | CAPN1 (0.39) | CAPN1CTSS | |
| SCHEMBL22895907 | 0.83 | CAPN1 (0.41) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | USP30 748/4885CAPN1 3/4885RAB9A 2461/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | USP30 531/4885CAPN1 4/4885RAB9A 2055/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | USP30 748/4885CAPN1 3/4885RAB9A 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.